Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Federal judge throws out Purdue Pharma’s opioid settlement that protected Sackler family

By Brian Buntz | December 17, 2021

Purdue PharmaColleen McMahon of the U.S. District Court for the Southern District of New York overturned a sweeping settlement against Purdue Pharma over its role in the opioid crisis.

Purdue’s Oxycontin (oxycodone) is among the most widely used opioids.

In September, Judge Robert Drain of the U.S. Bankruptcy Court in White Plains, New York, authorized a Chapter 11 bankruptcy settlement against the company. However, several states involved in the suit vowed to appeal the decision.

McMahon argued that the agreement should not have shielded the Sackler family that owned Purdue Pharma from civil liability for opioid-related lawsuits.

The Sacklers had sought immunity from opioid claims as part of the $4.5 billion agreement.

In a 2007 plea agreement with the U.S., Purdue Pharma acknowledged that it had marketed OxyContin inappropriately and submitted false claims to the federal government related to the drug.

McMahon’s ruling will likely mean that the case is headed for the U.S. Court of Appeals for the Second Circuit.

In her appeal, McMahon describes the issue of immunity in the case as a “great unsettled question” and says it is not clear if any court is “statutorily authorized to grant such releases.”

“This issue has split the federal Circuits for decades,” she continued. “While the Circuits that say no are united in their reasoning, the Circuits that say yes offer various justifications for their conclusions.”

Earlier this year, members of the House of Representatives introduced proposed legislation known as “The Sackler Act” to stop bankruptcy courts from shielding business owners from such protections unless they file for bankruptcy as individuals.

Purdue Pharma filed for Chapter 11 bankruptcy in 2019.

Tell Us What You Think! Cancel reply

Related Articles Read More >

Seagen
Seagen CEO Siegall resigns after domestic abuse arrest
Moderna
Moderna’s new CFO leaves after former employer discloses investigation
Pfizer logo
Pfizer to shell out $11.6B for migraine drugmaker Biohaven
Novartis logo
Novartis temporarily halts production of two radioligand therapy medicines

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards